Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases

doi:10.3748/wjg.v21.i24.7584

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8418)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

605

WORD

183

HTML

4218

Tables (1-2)

193

Sum=5199

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1196

Download

2007

Sum=3203

Jun 28, 2015 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (86)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Gastroenterol. Jun 28, 2015; 21(24): 7584-7588
Published online Jun 28, 2015. doi: 10.3748/wjg.v21.i24.7584

Table 2 Clinical characteristics of patients in published cases

Case - Year	Age/Gender	Disease	Anti-TNF drug	Immunosuppressant	Dose mg/kg/n-infusions	Symptoms	Autoantibodies	Histology	Steroid response	Outcome
2007³	56/F	AS	IFX	None	5/6	Yes	Anti-dsDNA, ANA, ASMA	Piecemeal necrosis	Yes	Reversibility
2005⁴	53/F	PsA	IFX	MTX	3/8	No	Anti-dsDNA, ANA, ASMA	Severe interface hepatitis	Yes	Reversibility
2007¹²	54/F	RA	IFX	MTX	3/12	No	ANA	Chronic inflammation	Yes	Reversibility
2010⁷	60/M	CD	IFX	None	5/4	No	Anti-dsDNA, ANA, ASMA	Interface hepatitis	Yes	Reversibility
2009⁸	22/F	PPP	IFX	None	5/3	No	None	Interface hepatitis	Yes	Reversibility
2010¹⁰	40/F	PsO, PsA	IFX	NSAIDS	5/5	Yes	Anti-dsDNA, ANA	Chronic hepatitis with portal+periportal fibrosis	Yes	Reversibility
2010⁹	37/M	PsO	IFX	None	5/3	Yes	Anti-dsDNA, ANA, ASMA Anti-dsDNA, ANA, AMA, anti-cardiolipin	Interface hepatitis	Yes	Reversibility
2010⁹	51/M	PsO	IFX	None	5/3	Yes		Interface hepatitis + PBC Overlap syndrome	Yes	Reversibility
2001¹¹	36/F	RA	IFX	PDN 10 mg	3/3	Yes	Anti-dsDNA, ANA	Interface hepatitis	Yes	Reversibility
2010⁶	36/F	PsA, PsO, CD	ADA	None	40 mg EOW 6^th injection	Yes	Anti-dsDNA, ANA	Interface hepatitis	Yes	Reversibility
2012¹²	46/F	CD	IFX	None	5/3	No	ANA, ASMA	Interface hepatitis	Yes	Reversibility
2008⁵	30/F	UC	IFX	AZA	10/> 15	No	ANA,Anti-dsDNA	Interface hepatitis	Yes	Reversibility

AS: Ankylosing spondylitis; PsA: Psoriatic arthritis; RA: Rheumatoid arthritis; CD: Crohn’s disease; PPP: Palmoplantar pustular psoriasis; PsO: Psoriasis; IFX: Infliximab; ADA: Adalimumab; MTX: Methotrexate; AZA: Azathioprine; EOW: Every other week; dsDNA: Double stranded DNA; ASMA: Anti-smooth muscle antibodies; AMA: Anti-mitochondrial antibodies; PDN: Prednisolone; NSAIDs: Non-steroidal anti-inflammatory drugs; PBC: Primary biliary cirrhosis.

Citation: Rodrigues S, Lopes S, Magro F, Cardoso H, Horta e Vale AM, Marques M, Mariz E, Bernardes M, Lopes J, Carneiro F, Macedo G. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases. World J Gastroenterol 2015; 21(24): 7584-7588
URL: https://www.wjgnet.com/1007-9327/full/v21/i24/7584.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i24.7584